

Contents

Preface *xiii*

1	Exploring Protein–Protein Interactions: Concepts, Methods, and Implications	1
	<i>Mi Zhou and Renxiao Wang</i>	
1.1	General Concepts of Protein–Protein Interactions	1
1.1.1	Definition of Protein–Protein Interactions	1
1.1.2	Structural Properties of Protein–Protein Interactions	2
1.1.3	Diverse Types of Protein–Protein Interactions	3
1.1.3.1	Enzyme–Substrate Interactions	3
1.1.3.2	Receptor–Ligand Interactions	3
1.1.3.3	Antigen–Antibody Interactions	3
1.1.3.4	Chaperone–Client Interactions	4
1.1.3.5	Scaffold Interactions	4
1.2	Functional Significance of Protein–Protein Interactions	4
1.2.1	Cellular Signal Transduction	5
1.2.2	Regulation of Gene Expression	6
1.2.3	Immune Response	8
1.2.3.1	Immune Cell Migration	8
1.2.3.2	T-Cell Antigen Recognition and Activation	8
1.2.3.3	B-Cell Antigen Recognition and Activation	9
1.2.4	Protein Degradation Pathway	9
1.2.5	Disease Mechanisms	10
1.2.5.1	Cancer	10
1.2.5.2	Neurodegenerative Diseases	11
1.2.5.3	Infectious Disease	11
1.3	Methods for Analyzing Protein–Protein Interactions	12
1.3.1	Experimental Methods	12
1.3.1.1	Structure Determination	12
1.3.1.2	Affinity, Kinetics, and Thermodynamics Measurement	13
1.3.1.3	Large-Scale PPI Network Mapping	13
1.3.2	Computational Methods	14
1.3.2.1	Sequence-Based Methods	14
1.3.2.2	Structure-Based Methods	15

1.3.2.3	Network-Based Methods	15
1.4	Implications of the Basic Research on Protein–Protein Interactions	16
1.4.1	Advancing Disease Understanding and Diagnosis	16
1.4.2	Driving Target-Based Drug Discovery	17
1.4.3	Fostering Innovations in Biotechnology	17
1.5	Conclusions and Perspectives	19
	References	19
2	Overview of Drug Discovery Targeting PPI Systems	29
	<i>Hao Ma and Jian Zhang</i>	
2.1	Introduction	29
2.2	Fundamentals of Protein–Protein Interactions	30
2.2.1	Basic Principles of Protein Structure and Function	30
2.2.2	Types of Protein–Protein Interactions	32
2.2.3	Significance of PPIs in Cellular Processes and Disease Pathways	32
2.3	Challenges in Targeting PPI Systems	33
2.3.1	Structural Complexities of PPI Interfaces	33
2.3.2	Dynamics and Flexibility of Protein Complexes	34
2.3.3	Druggability Issues Associated with PPI Targets	35
2.4	Approaches in Drug Discovery Targeting PPI Systems	35
2.4.1	High-Throughput Drug Design (HTS) Methods	35
2.4.2	Structure-Based Drug Design (SBDD) Techniques	36
2.4.3	Fragment-Based Drug Discovery (FBDD) Strategies	37
2.4.4	Computational Methods for Predicting PPI Inhibitors	38
2.5	Case Studies and Success Stories	40
2.5.1	BCL Family	40
2.5.1.1	Bcl-2	40
2.5.1.2	Bcl-xL	42
2.5.1.3	MCL-1	42
2.5.2	p53–MDM2	43
2.5.3	XIAP/c-IAP1	44
2.5.4	CD40-CD40L	45
2.5.5	Cyclin-Dependent Kinase (CDK)	46
2.5.6	PD-1/PD-L1	47
2.5.7	Hsp90-Cdc37	48
2.5.8	Menin-MLL	48
2.5.9	Kras-SOS1	49
2.5.10	Keap1-Nrf2 PPI	49
2.6	Conclusion	51
	References	53
3	Fluorescence Resonance Energy Transfer Technology and its Applications	61
	<i>Jing-Yu Lang</i>	
3.1	Introduction	61
3.2	Mechanism of FRET	61
3.3	Applications of FRET	63

- 3.3.1 Molecular Interactions 63
- 3.3.2 Conformational Changes 64
- 3.3.3 Cellular Imaging 64
- 3.3.4 Drug Discovery 64
- 3.3.5 Clinical Diagnosis 65
- 3.3.6 Structural Biology 66
- 3.3.7 Materials Science 66
- 3.3.8 Environmental and Agricultural Sciences 66
- 3.4 Advantages and Limitations 67
- 3.5 Recent Advances 68
- 3.6 Conclusion 70
- Acknowledgements 71
- References 71

- 4 Dissect Protein Interactions Using Mass Spectrometry 75**
Bin Liao and Liang Zhang
- 4.1 Introduction 75
- 4.2 Affinity Purification Coupled with Mass Spectrometry (AP-MS) 76
- 4.3 Proximity Labeling 81
- 4.4 Cross-linking Mass Spectrometry (XL-MS) 84
- 4.5 Co-fractionation Coupled with Mass Spectrometry (CF-MS) 88
- 4.6 Thermal Proximity Co-aggregation (TPCA) 90
- 4.7 Limited Proteolysis–Mass Spectrometry (LiP–MS) 93
- 4.8 Conclusion and Outlook 95
- Acknowledgements 96
- References 96

- 5 Detection of Protein–Protein Interactions In Situ via Proximity Ligation Assay 105**
Xinyue Zhou and Peng Zou
- 5.1 Introduction 105
- 5.2 Implementations of Proximity Ligation Assay 106
- 5.3 Applications of PLA for Detecting Protein–Protein Interactions 108
- 5.4 Conclusions and Outlooks 109
- Acknowledgments 110
- References 110

- 6 Application of Surface Plasmon Resonance in the Characterization of Protein–Protein Interactions 115**
Yuanyuan Xie and Jianrong Xu
- 6.1 Introduction 115
- 6.1.1 Protein–Protein Interactions 115
- 6.1.2 Principle of Surface Plasmon Resonance 115
- 6.1.3 Advantage of SPR 116
- 6.2 Applications of SPR Assays in PPIs Characterization 117
- 6.2.1 SPR Application in Binary PPI Systems 117
- 6.2.1.1 SPR Assay in Verifying and Measuring PPIs 117

6.2.1.2	SPR-Guided Screening and Optimization in Drug Discovery	120
6.2.1.3	SPR in the Validation of PPI Interface	123
6.2.2	SPR Application in Ternary PPI Systems	126
6.2.2.1	SPR-Based Epitope Competition Assays	126
6.2.2.2	SPR-Based Drug Discovery of PPI Modulators	128
6.2.2.3	SPR Applications in Targeted Protein Degradation	130
6.3	Advantages and Limitations of SPR Application for PPIs	131
6.4	Future Directions	132
	References	133

7 Computational Methods for Protein–Protein Interactions

Hao Li, Yurui Li, and Sheng-You Huang

7.1	Introduction	139
7.2	Protein–Protein Docking	140
7.2.1	Sampling	142
7.2.1.1	Traditional Search Algorithms	142
7.2.1.2	Deep Learning-Based Search Algorithms	144
7.2.2	Scoring	145
7.2.2.1	Traditional Scoring Function	145
7.2.2.2	Deep Learning-Based Scoring Function	146
7.2.3	Template-based Docking	147
7.3	End-to-end Structure Prediction	148
7.4	CAPRI Experiments	151
7.4.1	CASP13-CAPRI	152
7.4.2	CASP14-CAPRI	152
7.4.3	CASP15-CAPRI	153
7.5	Challenges and Future Directions	154
	Acknowledgments	155
	Author Contributions	155
	References	155

8 Foldamers as Inhibitors of Aberrant Protein–Protein Interactions

Nicholas H. Stillman, Ryan A. Dohoney, Charles Z. Baysah, and Sunil Kumar

8.1	Introduction	163
8.2	The Evolution of Hamilton’s Oligopyridylamides	164
8.3	Limitations of a Tedious Synthetic Route	165
8.4	OPs as Antagonists of Neurodegeneration	166
8.5	OPs Inhibit HIV Infection	168
8.6	OPs Targeting Type II Diabetes	169
8.7	OPs Targeting and Reactivating Mutant Protein in Cancer	171
8.8	Novel Synthesis of OPs and Alzheimer’s Disease	173
8.9	2D-FAST	174
8.10	OQ Foldamers – Structure and Discovery	181
8.11	Synthesis of OQ Foldamers	182

8.12	OQs as Modulators of Type II Diabetes-Related aPPIs	183
8.13	Mechanistic Insights into OQ Manipulation of aPPIs	186
8.14	Chemical Diversity and Structure Modulate Efficacy of OQs	188
8.15	Modulation of Alzheimer's Disease-Related A β	189
8.16	OQs for the Modulation of Synucleinopathies	191
8.17	Epilogue	194
	Acknowledgement	194
	References	195
9	Application of Sulfonyl-γ-AApeptides for PPI Drug Discovery	205
	<i>Jarais Fontaine and Jianfeng Cai</i>	
9.1	Introduction	205
9.2	Application of Sulfonyl- γ -AApeptides	206
9.2.1	Modulation of PPIs Involved in Cancer	206
9.2.1.1	Inhibition of β -catenin/B-cell lymphoma 9 PPIs	206
9.2.1.2	p53-MDM2/MDMX PPIs Inhibitor	208
9.2.1.3	HIF-1 α PPI's Inhibitor	209
9.2.2	Anti-Viral	210
9.2.2.1	HIV Fusion Inhibitor	210
9.2.2.2	Pan-Coronavirus Fusion inhibitor	212
9.2.3	A β -Oligomerization Modulation	213
9.2.4	Diabetes Therapeutics	216
9.3	Future Directions/Conclusion	216
	Acknowledgments	217
	References	217
10	Introduction of the Application of Stapled Peptides in Protein-Protein Interactions Drug Discovery and Their Successful Examples	219
	<i>Maxwell J. Austin and Danny Hung-Chieh Chou</i>	
10.1	Introduction	219
10.1.1	Stapled Peptides as a Solution to PPI Challenges	219
10.1.2	Growing Importance of PPIs in Drug Discovery	220
10.1.3	Early Development and Success of Stapled Peptides	220
10.1.4	Overview of the Chapter	221
10.2	Stapled Peptides: Structure Features and Benefits	221
10.2.1	Importance of α -Helical Structures in PPIs	221
10.2.2	Designing Stapled Peptides: Mechanism of Stapling	221
10.2.3	Additional Stapling Strategies	222
10.2.3.1	Lactamization Between Lysine and Glutamate/Aspartate	222
10.2.3.2	Azide-Alkyne Cycloaddition	223
10.2.3.3	C—H Activation	224
10.2.3.4	Cys-Cys Initiated Stapling Strategy	224
10.2.3.5	Tyrosine Stapling	224
10.2.4	Advantages of Stapled Peptides in Drug Discovery	225

- 10.2.4.1 Enhanced Proteolytic Stability 225
- 10.2.4.2 Improved Cell Permeability 226
- 10.2.4.3 Ability to Target Previously “Undruggable” PPIs 226
- 10.2.4.4 Specificity and Affinity Considerations 227
- 10.3 Successful Applications of Stapled Peptides in Drug Discovery 227
 - 10.3.1 Targeting the MDM2–p53 Interaction 227
 - 10.3.2 Targeting BCL-2 Family Proteins 228
 - 10.3.3 Targeting the β -Catenin/TCF Interaction 229
 - 10.3.4 Infectious Diseases 230
 - 10.3.5 Clinical Progress and Future Directions 231
- 10.4 Challenges and Limitations 232
 - 10.4.1 Manufacturing and Cost Considerations 232
 - 10.4.2 Delivery Issues: Overcoming Biological Barriers 232
 - 10.4.3 Off-Target Effects and Safety Concerns 233
 - 10.4.4 Resistance Mechanisms 233
- 10.5 Future Directions 234
 - 10.5.1 Expansion into New Disease Areas 234
 - 10.5.2 Integration with Other Therapeutic Modalities 235
 - 10.5.3 Emerging Delivery Technologies 235
 - 10.5.4 Summary 236
- Acknowledgments 237
- References 237
- 11 Cyclic Peptides for PPI Drug Discovery 243**
Hong-Gang Hu and Xiang Li
 - 11.1 Introduction 243
 - 11.2 α -Helix Cyclic Peptides (Stapled Peptides) 244
 - 11.2.1 Antitumor Stapled Peptides 245
 - 11.2.2 Antiviral Stapled Peptides 251
 - 11.2.3 Anti-osteoporosis Stapled Peptides 252
 - 11.2.4 Anti-inflammation Stapled Peptides 253
 - 11.2.5 Anti-diabetes Stapled Peptides 253
 - 11.3 β -Hairpin Cyclic Peptides 253
 - 11.4 Macrocyclic Peptides 255
 - 11.5 Summary and Outlook 255
 - References 256
- 12 Small Molecule Inhibitors Targeting Protein–Protein Interactions in the BCL Protein 263**
Wenhua Zhu, Yangbo He, Gang Chen, and Di Zhu
 - 12.1 Introduction 263
 - 12.2 Inhibitors of BCL-2 Family Antiapoptotic Proteins 264
 - 12.2.1 Members and Structure of BCL-2 Family Proteins 264
 - 12.2.2 Binding Sites and Key Interactions of BCL-2 Family Proteins 266
 - 12.2.3 Antiapoptotic Proteins of the BCL-2 Family and Cancer 267
 - 12.2.4 BCL-2 Family Antiapoptotic Protein Inhibitors 267
 - 12.2.4.1 Selective Bcl-2/Bcl-xL Inhibitors 268

- 12.2.4.2 Selective Mcl-1 Inhibitor 280
- 12.2.4.3 Compounds 54-59 292
- 12.3 Inhibitors of β -catenin/BCL9 300
 - 12.3.1 Physiological Functions of BCL9 300
 - 12.3.2 β -catenin/BCL9 PPI 300
 - 12.3.3 Targeting β -catenin/BCL9 Small Molecule Inhibitors 301
 - 12.3.3.1 Natural Products and Their Derivatives 301
 - 12.3.3.2 Phenyl-piperidine Derivatives 303
 - 12.3.3.3 3-(4-fluorophenyl)-*N*-phenylbenzamide Derivatives 305
 - 12.3.3.4 Other β -catenin/BCL9 Small Molecule Inhibitors 307
 - 12.4 Targeting BCL-6 Small Molecule Inhibitors 307
 - 12.4.1 Biological Functions of BCL6 307
 - 12.4.2 Structural Characteristics of the BCL6 BTB/POZ Domain 308
 - 12.4.3 BCL6-targeted Diseases 309
 - 12.4.4 BCL6 Inhibitor 310
 - 12.4.4.1 79-6, FX1 and AP-4-287 310
 - 12.4.4.2 BI3812 and TMX-2164 310
 - 12.4.4.3 BCL6-i and Compound 107 316
 - 12.4.4.4 Compounds 109, 111, WK500B, and GSK137 316
 - 12.4.4.5 CCT369347, CCT372064, and OICR12694 317
 - 12.5 BCL-3 Inhibitors 318
 - 12.5.1 Structural Characteristics of BCL-3 318
 - 12.5.2 Biological Functions of BCL-3 318
 - 12.5.3 BCL-3/P50 Inhibitors 320
 - 12.6 BCL-10 Inhibitors 320
 - 12.6.1 Biological Functions of BCL-10 320
 - 12.6.2 Structural Characteristics of BCL-10 321
 - 12.6.3 BCL-10 and Cancer 322
 - 12.7 Summary 322
 - References 323
- 13 Molecular Glues as Activators for PPI 343**
Xiangbing Qi
 - 13.1 Introduction 343
 - 13.1.1 Significance of PPI in Biology and Disease 343
 - 13.1.2 Opportunities and Challenges for PPI Drug Discovery 344
 - 13.1.3 Four Classes of PPI Modulators 344
 - 13.2 Molecular Glues as Orthosteric PPI Stabilizers/Activators 347
 - 13.2.1 Design Principles of MG 347
 - 13.2.2 Classification of MGs 347
 - 13.2.2.1 MG Degradors (MGDs) 347
 - 13.2.2.2 MG Stabilizers 354
 - 13.2.2.3 MG Inhibitors 357
 - 13.3 Methods for MG Discovery 358
 - 13.3.1 Modifications of E3 Ligands: Discovery of New CRBN Ligands 360
 - 13.3.2 Phenotype-Based Screening 361

13.3.2.1	Scalable Chemical Profiling	361
13.3.2.2	Proteomics-Based Screening	362
13.3.3	Target-Based Screening	363
13.3.3.1	HTS for PPI Stabilizers	363
13.3.3.2	Rational Design: Discovery of KRAS-CYPA Molecular Glue	363
13.4	Conclusions and Outlook	364
	Contributors	364
	References	364
14	Targeting APC–Asef Protein–Protein Interaction for Drug Discovery in Colorectal Cancer Therapy	373
	<i>Jie Zhong and Xiuyan Yang</i>	
14.1	Introduction	373
14.2	Structural Insights into APC–Asef Interaction	375
14.3	Current APC–Asef Inhibitors	376
14.3.1	Peptides	376
14.3.1.1	Minimal Asef Sequence for APC	376
14.3.1.2	MAI-150–Derived Peptidomimetic Inhibitors	377
14.3.1.3	MAI-203 as the First-in-Class Inhibitor of APC–Asef PPI with Anti-CRC Migration Activity	377
14.3.1.4	Intramolecular Hydrogen Bond Strategy Leading to the Best-in-Class Inhibitor MAI-400	379
14.3.1.5	A More Sensitive FP Assay Led to the Discovery of a Highly Efficient and Potent Inhibitor, MAI-516	380
14.3.1.6	Computer-Aided Design of Tripeptide Inhibitors Disrupting APC–Asef Interaction	381
14.3.2	Small Molecule Inhibitors of APC–Asef PPI	381
14.4	A More Sensitive FP Method for Identifying Highly Active APC–Asef Inhibitors	382
14.5	Conclusions and Outlook	383
	References	385
15	Computational Methods Applied to Drug Discovery of Protein–Protein Interaction Systems	389
	<i>Zhiyong Gu and Xi Cheng</i>	
15.1	Introduction	389
15.2	Computational Methods for PPI Prediction	390
15.2.1	PPI Network Mapping	390
15.2.2	Protein Complex Prediction	394
15.2.3	PPI Modulator Discovery	395
15.2.3.1	Small Molecules	397
15.2.3.2	Peptides and Protein Mimics	400
15.2.3.3	Antibodies	401
15.3	Conclusions and Outlook	401
	References	402
	Index	409